Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07497425

Neuroimmune Responses to Exercise in Chronic Back Pain

The goal of this mechanistic clinical trial is to learn how physical exercise affects the body and brain in people with chronic low back pain. The study will examine whether a 12-week online exercise program changes these measures compared with a waitlist group. Researchers will also study immune activity and brain function in people with chronic low back pain and compare them with healthy participants. Participants will complete questionnaires, provide blood samples, and undergo brain imaging scans.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Montreal General Hospital

Montreal, Quebec, H3H 1V6, Canada

Location status: Recruiting

Location contact

Carlos Gevers Montoro, PhD

CONTACT

[email protected]

+1-8199790448

About this study

Chronic low back pain (CLBP) is the leading cause of disability worldwide, yet its underlying mechanisms remain poorly understood, limiting treatment effectiveness. Growing evidence suggests that CLBP is not solely driven by peripheral tissue pathology but involves maladaptive interactions between the immune system and the brain, particularly within reward- and emotion-related brain circuits. Physical exercise (PE) is universally recommended for CLBP and is known to influence both inflammatory processes and brain function, but the neuroimmune mechanisms through which PE alleviates pain are largely unknown. This study aims to address this critical gap by characterizing immune, neural, and autonomic alterations in CLBP and their modulation through structured PE training.

In this mechanistic randomized controlled trial, 144 individuals with CLBP will be randomized to a 12-week online PE program or a waitlist control, and 72 age- and sex-matched healthy controls will serve as comparators for baseline values and response to acute PE. Participants will undergo comprehensive assessments including questionnaires, movement-evoked pain testing, quantitative sensory testing, heart rate variability, blood sampling for immune gene expression (through whole blood transcriptomics), and multimodal MRI. Acute immune and autonomic responses to initial exercise sessions will also be examined to test whether short-term pro-inflammatory responses initiate longer-term adaptive and analgesic processes. By integrating immune, brain, and behavioral data, this study seeks to elucidate how neuroimmune interactions contribute to CLBP persistence and recovery, providing mechanistic insights to optimize exercise-based treatments.

In June 2025, the investigators initiated an initial pilot phase within the present trial to determine the feasibility of our recruitment strategies (recruitment of patient cohorts of 5-8 patients who will receive the PE intervention or be waitlisted according to block randomization) and compliance with the exercise program/waitlist protocol, and all intermediary data collection points. Feasibility was confirmed in February 2026, and recruitment of subsequent cohorts is planned to continue in March 2026. All future data collection will use the same core procedures and outcomes as the pilot phase, therefore, data collected during the pilot phase will be retained and may be included in the final analyses where appropriate.

At the time of this registration, preliminary analyses have only been conducted for the primary clinical outcome (pain intensity) as part of our assessment of feasibility. No inferential analyses have been conducted. Analyses of biological and neuroimaging measures, including transcriptomic and brain imaging data, are contingent on funding acquisition.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-CLBP patients:

  • Have a diagnosis of chronic primary LBP, according to the criteria established by NIH Task Force on Research Standards for CLBP (Deyo et al., 2015). This will be determined by 1) the response to the National Institutes of Health minimum dataset for CLBP (NIH-md), including that LBP has been persistent for at least 3 months or recurrent for at least half of the days in the past 6 months, and 2) the results of a complete case history and physical examination (including functional tasks, quantitative sensory testing, and, if needed, neuro-orthopedic, palpation and range of motion assessments);
  • Report a CLBP intensity of at least 4 in a 0-10 numerical rating scale (0 = no pain, 10 = maximum possible pain).

Inclusion criteria

-Healthy controls:

  • Be over 18 years and under 75 years of age;

Exclusion criteria

-CLBP patients:

  • Present any red flags indicative of serious pathology comorbid or as the cause of CLBP (Finucane et al., 2020);
  • Have a CLBP phenotype characterized by predominant nociceptive (as in fracture, infection, malignancy, inflammatory or rheumatic spondyloarthropathy, cauda equina syndrome, confirmed by MRI when suspected) or neuropathic pain mechanisms, the latter assessed through score in the DN4 questionnaire (Nijs, et al., 2024);
  • Present chronic or acute pain of higher intensity or perceived disability in any other body site than the low back;
  • Medical history of diabetes, neurological or psychiatric disorder;
  • Presence of significant cardiorespiratory problems or any other potential contraindications to physical exercise as assessed through the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+);
  • Following a regular structured PE training program (>60 min/week) at study's onset, and;
  • Presence of any contraindications to MRI examination (including any metallic implants or devices, being pregnant, and claustrophobia).

Exclusion criteria

-Healthy controls:

  • Have symptoms or a diagnosis of any acute or chronic pain conditions;
  • Medical history of diabetes, neurological or psychiatric disorder;
  • Presence of significant cardiorespiratory problems or any other potential contraindications to physical exercise as assessed through the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+);
  • Following a regular structured PE training program (>60 min/week) at study's onset, and;
  • Presence of any contraindications to MRI examination (including any metallic implants or devices, being pregnant, and claustrophobia).

Treatment and study plan

Physical exercise

Behavioral

Patients in the PE training group will perform a 12-week online program comprising three 60-minute weekly training sessions. The training program is delivered by certified kinesiologists through a secured online platform.

Healthy controls will participate only in the first 2 weeks of PE training.

Primary outcomes

  1. Chronic Low Back Pain Intensity

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12). In addition, assessed daily through electronic pain diaries.

    Self-reported low back pain intensity averaged over the past 7 days, measured using an 11-point Numerical Rating Scale (NRS; 0-10), where 0 = "no pain" and 10 = "worst imaginable pain." Item from the NIH minimum dataset on research standards for chronic low back pain. Data collected in REDCap.

Secondary outcomes

  1. Peripheral Blood Gene Expression (RNA Sequencing)

    Time frame: Blood samples collected at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12). In addition, samples also collected 14, 48 hours and 2 weeks after the first exercise session or at equivalent times for waitlist participants

    Gene expression levels assessed in peripheral blood using RNA sequencing. Transcriptomic analyses evaluated differential gene expression and pathway analyses.

  2. Nucleus Accumbens-Medial Prefrontal Cortex Functional Connectivity

    Time frame: MRI acquired at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Functional connectivity assessed using resting-state functional magnetic resonance imaging (rsfMRI). Seed-to-voxel analyses performed using anatomically defined bilateral nucleus accumbens and medial prefrontal cortex regions.

  3. Fractional Anisotropy of NAc-mPFC White Matter Tract

    Time frame: MRI acquired at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Fractional Anisotropy (FA) measured using diffusion-weighted imaging (DWI) probabilistic tractography along the white matter connecting the nucleus accumbens and medial prefrontal cortex.

  4. Whole-Brain Intrinsic Connectivity

    Time frame: MRI acquired at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Intrinsic connectivity analysis (voxel-wise network centrality; root mean square of all functional connections) performed using resting-state functional magnetic resonance imaging (rsfMRI) to quantify whole-brain functional connectivity.

  5. Tonic Pain Signature (ToPS)

    Time frame: MRI acquired at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Expression of the Tonic Pain Signature (ToPS), a multivariate brain biomarker derived from whole-brain functional connectivity patterns predictive of sustained pain intensity. The ToPS score will be computed from resting-state fMRI data using validated model weights and applied to participant-level connectivity matrices.

  6. Nociplastic Functional Signature (NFS)

    Time frame: MRI acquired at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Expression of the Nociplastic Functional Signature (NFS), a brain-based connectivity biomarker trained to classify nociplastic pain conditions. NFS scores will be calculated from resting-state fMRI connectivity patterns to quantify the presence of nociplastic pain-related network dysconnectivity.

  7. Hippocampal volume

    Time frame: MRI acquired at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Structural volume of the bilateral hippocampus measured from T1-weighted anatomical MRI using automated segmentation. Hippocampal volume alterations have been reported in chronic pain populations and may reflect changes associated with pain chronification.

  8. Superior Longitudinal Fasciculus (SLF) White Matter Integrity

    Time frame: MRI acquired at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Microstructural integrity of the Superior Longitudinal Fasciculus (SLF) assessed using DWI metrics (fractional anisotropy, mean diffusivity). The SLF is a major fronto-parietal white-matter tract implicated in cognitive control, attention, and pain modulation networks. Loss of integrity in this tract may be associated with chronic pain severity.

  9. Heart rate variability: RMSSD

    Time frame: ECG will be collected at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12). In addition, ECG also conducted 14, 48 hours and 2 weeks after the first exercise session or at equivalent times for waitlist participants

    Heart rate variability will be assessed using the root mean square of successive differences (RMSSD), a time-domain measure reflecting parasympathetic (vagal) cardiac modulation. 5 minutes of resting electrocardiogram (ECG) signals will be recorded using BIOPAC systems and processed using Kubios HRV software.

  10. NIH minimum dataset pain impact stratification subscale

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Pain-related impact (pain impact stratification, 9 items 0-50), higher scores indicate greater pain impact on function. Data collected in REDCap.

  11. NIH minimum dataset emotional depression and distress subscale

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Pain-related emotional depression and distress (EDD, 4 items 0-16), higher scores indicate greater pain impact on this dimension. Data collected in REDCap.

  12. NIH minimum dataset sleep disturbance subscale

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Pain-related sleep disturbance (SlD, 2 items 0-8), higher scores indicate greater pain impact on this dimension. Data collected in REDCap.

  13. Oswestry Low Back Pain Disability Index (ODI)

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Pain-related disability measured using the Oswestry Low Back Pain Disability Questionnaire (10 items). Each item is scored from 0-5, yielding a total score ranging from 0-50, with higher scores indicating greater disability. Data collected in REDCap.

  14. Fatigue severity scale

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The Fatigue Severity Scale (FSS) assesses the impact of fatigue on daily functioning. The questionnaire contains 9 items, each rated on a 7-point Likert scale (1-7). Scores are averaged across items, with higher scores indicating greater fatigue severity and functional impairment. Data collected in REDCap.

  15. Pittsburgh sleep quality index

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The Pittsburgh Sleep Quality Index (PSQI) assesses sleep quality and sleep disturbances over the past month. The instrument contains 19 self-rated items, generating 7 component scores summed into a global score ranging from 0 to 21, with higher scores indicating poorer sleep quality. Data collected in REDCap.

  16. Snaith-Hamilton pleasure scale

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The Snaith-Hamilton Pleasure Scale (SHAPS) assesses anhedonia (reduced ability to experience pleasure). The scale contains 14 items evaluating pleasure responses to everyday experiences. Total scores range from 0 to 14, with higher scores indicating greater anhedonia. Data collected in REDCap.

  17. Multiple abilities self-assessed questionnaire

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The Multiple Ability Self-Report Questionnaire (MASQ) assesses self-perceived cognitive functioning in everyday life, including language, memory, attention, and visuospatial abilities. The questionnaire contains 38 items rated on a 5-point Likert scale. Total scores range from 38 to 190, with higher scores indicating greater perceived cognitive difficulties, as well as five subscales for specific cognitive dimensions: Language, Verbal Memory, Visual Memory, Visuo-perceptual Ability, and Attention/Concentration. Data collected in REDCap.

  18. Movement-evoked pain

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Movement-evoked pain (MeP) will be assessed as the difference between pain at rest and the peak pain intensity reported during or immediately after four movement tasks: balance, sit-to-stand, a tailored provocative movement, and a tailored lifting task. Pain intensity will be rated using a 0-10 Numerical Rating Scale (NRS) before, during and after each task. MeP is calculated with the formula (Peak Pain During/After Task - Pain at Rest), for a score ranging from -10 to +10. An aggregate MeP score will also be calculated as the sum of the score obtained from each task (ranging from -40 to +40).

Other outcomes

  1. Pain Catastrophizing Scale

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The Pain Catastrophizing Scale (PCS) assesses catastrophic thinking related to pain, including rumination, magnification, and helplessness. The scale contains 13 items rated on a 5-point scale (0-4). Total scores range from 0 to 52, with higher scores indicating greater pain catastrophizing. Data collected in REDCap.

  2. Tampa Scale of Kinesiophobia

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The Tampa Scale of Kinesiophobia (TSK) assesses fear of movement and injury related to pain. The questionnaire contains 17 items rated on a 4-point Likert scale. Total scores range from 17 to 68, with higher scores indicating greater fear of movement. Data collected in REDCap.

  3. Pain Self-Efficacy Questionnaire

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The Pain Self-Efficacy Questionnaire (PSEQ) assesses confidence in performing activities despite pain. The questionnaire contains 10 items rated on a 7-point scale (0-6). Total scores range from 0 to 60, with higher scores indicating greater pain self-efficacy. Data collected in REDCap.

  4. Beck Depression Inventory

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The Beck Depression Inventory-II (BDI-II) assesses severity of depressive symptoms. The instrument contains 21 items rated on a 4-point scale (0-3). Total scores range from 0 to 63, with higher scores indicating greater depressive symptom severity. Data collected in REDCap.

  5. State anxiety inventory

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    The State Anxiety Inventory (STAI-State) assesses current levels of anxiety. The questionnaire contains 20 items rated on a 4-point scale. Total scores range from 20 to 80, with higher scores indicating greater state anxiety. Data collected in REDCap.

  6. Pressure pain thresholds

    Time frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 12)

    Pressure pain thresholds (PPTs) will be measured in kgs using a Wagner FDx algometer. The PPT will be defined as the arithmetic mean of four consecutive measurements taken at two sites bilaterally: (1) the lumbar paraspinal or gluteal muscle, 2 cm lateral to the spinous process or posterior superior iliac spine of the participant's most painful lumbar segment, and (2) the thumbnail bed.

  7. Adverse reactions to physical exercise sessions

    Time frame: Immediately after each PE session (Monday, Thursday, and Weekend for 12 weeks)

    After each individual exercise sessions, participants will be asked to complete a short questionnaire to assess whether an adverse reaction to physical exercise (yes/no and details) was experienced. This item will also serve to monitor adherence. Data collected in REDCap.

  8. Pain related to physical exercise sessions

    Time frame: Immediately after each PE session (Monday, Thursday, and Weekend for 12 weeks)

    After each individual exercise sessions, participants will be asked to complete a short questionnaire to assess pain during and after exercise in a 0-10 NRS. Data collected in REDCap.

  9. Effort during physical exercise sessions

    Time frame: Immediately after each PE session (Monday, Thursday, and Weekend for 12 weeks)

    After each individual exercise sessions, participants will be asked to complete a short questionnaire to assess effort during the exercise in a 0-100 Borg scale. Data collected in REDCap.

  10. Fatigue due to physical exercise sessions

    Time frame: Immediately after each PE session (Monday, Thursday, and Weekend for 12 weeks)

    After each individual exercise sessions, participants will be asked to complete a short questionnaire to assess fatigue after exercise in a 0-10 NRS. Data collected in REDCap.

Study contacts

Contact information is provided by the study sponsor or research team.

Carlos Gevers Montoro, PhD

CONTACT

[email protected]

+1-8199790448

Sponsors and collaborators

Lead sponsor

McGill University

Other

Registry information

Official study title

Neuroimmune Responses to Physical Exercise Training in Chronic Primary Low Back Pain

Acronym: eCLBP

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
Mar 27, 2026
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.